Business Context and Reporting Period
This Form 8-K filing by Mast Therapeutics, Inc. (not Savara Inc.) reports on the Annual Meeting of Stockholders held on June 15, 2016. The company is incorporated in Delaware and is based in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to a vote of security holders:
- Proposal 1 (Election of Directors): All five nominees were elected. Significant broker non-votes (104,216,592) were recorded for this proposal. Votes against ranged from approximately 1.6 million to 4.1 million per nominee.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm. There were 135,242,840 votes for, 3,647,736 against, and 1,781,253 abstentions.
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation was approved. There were 28,097,329 votes for, 5,935,346 against, and 2,422,562 abstentions. Broker non-votes were 104,216,592.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the high volume of broker non-votes (over 104 million) on director and compensation proposals, which may indicate significant institutional holdings without voting instructions.
- Confirm the identity of the registrant as Mast Therapeutics, Inc., noting the discrepancy with the requested company name "Savara Inc."
- Review the definitive proxy statement for details on the executive compensation package that received advisory approval.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.